摘要
核苷酸切除修复系统(NER)的关键基因——切除修复交叉互补基因1(ERCC1),是各种基因损伤(包括铂类化合物引起的DNA损伤)的切除和修复过程中的重要一员。研究发现恶性肿瘤的发生、含铂方案化疗疗效及预后与ERCC1及其多态性关系密切,而且目前认为联合检测两种或多种生物标志物更有利于指导临床制定个体化治疗方案。本文着重综述ERCC1及其多态性与非小细胞肺癌的发生发展、接受含铂方案化疗疗效及预后的关系,以及现阶段与ERCC1联合检测的生物标志物的研究现状。
Excision repair cross-complementation group 1 （ERCC1） gene is the key gene of nucleotide excision repair system（NER）,there are many kinds of repair DNA damages including DNA damage caused by platinum drugs,and guided by combined detection of ERCC1 and other biomarkers,the individualized chemotherapy may improve therapeutic effective rate and prolong survival time in the malignant tumor. The study has found ERCC1 polymorphism is related to the incidence,therapeutic effect and prognosis of malignant tumor. This paper focuses on the relationship between ERCC1 polymorphism and NSCLC, including the development, chemotherapy efficacy and prognosis, and simply introducing the research of combined detection.
出处
《医学与哲学（B）》
2015年第7期74-77,共4页
Medicine & Philosophy(B)
关键词
非小细胞肺癌
ERCC1基因
基因多态性
铂类化合物
non-small cell lung cancer （NSCLC）, ERCC1 gene, gene polymorphism, platinum compound
